VHL is the most frequently mutated or inactivated tumor suppressor in RCC, with over 50% of RCC patients exhibiting a loss of VHL, making it a crucial biomarker for the discovery of therapeutic vulnerability in RCC. The gene discussed is VHL; the disease is renal cell carcinoma.